フルコナゾール
フルナゾール · 2,4-ジフルオロ-α,α-ビス[(1H-1,2,4-トリアゾール-1-イル)メチル]ベンゼンメタノール · 1,3-ビス(1H-1,2,4-トリアゾール-1-イル)-2-(2,4-ジフルオロフェニル)-2-プロパノール · フルタンゾール · トリフルカン · ビオゾレン · 1,3-ビス(1H-1,2,4-トリアゾール-1-イル)-2-(2,4-ジフルオロフェニル)プロパン-2-オール · フルコスタット
識別子と物理属性
| CAS No. | 86386-73-4 |
|---|---|
| 分子式 | C13H12F2N6O |
| 平均分子量 | 306.27 g/mol |
| 単同位体質量 | 306.10406544 g/mol |
| SMILES | OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F |
| InChIKey | RFHAOTPXVQNOHP-UHFFFAOYSA-N |
| PubChem CID | 3365 |
| ChEMBL | CHEMBL106 |
| ChEBI | CHEBI:46081 |
| EC No. | 627-806-0 |
| DTXSID | DTXSID3020627 |
| 現地名 | フルコナゾール |
化学・物理的性質
| XLogP | 0.4 |
|---|---|
| 極性表面積 | 81.7 |
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 7 |
| 回転可能結合数 | 5 |
| 重原子数 | 22 |
| 形式電荷 | 0 |
| 複雑度 | 358 |
| 物質分類 | Pharmaceutical |
| 医薬品 | Pharmaceuticals -> Listed in ZINC15Pharmaceuticals -> AntibioticsPharmaceuticals -> Anti infectives for systemic use -> Antibacterials for systemic usePharmaceuticals -> Used in Switzerland |
| 農薬 | Fungicides |
| LogP（分配係数） | 0.40.63 |
| Color/Form | White crystalline powderCrystals from ethyl acetate/hexane |
| 溶解度 | slightly soluble in waterPoorly soluble in water but can be dissolved in organic solvents such as chloroform, propylene glycol, and polyethoxylated castor oil (preparation for IV use but dangerous for dogs)Slightly soluble in water and saline1.39e+00 g/L34.9 [ug/mL] (The mean of the results at pH 7.4)DMSO: 5 mg/mL1g/L(温度表記なし) |
| Human Drugs | Breast FeedingLactationMilk, HumanAntifungal AgentsFDA approved drugs -> Active ingredientAntifungal medicines |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| 融点 | 138-140 °C138 - 140 °C138-140°C |
| Physical Description | Solid |
| Dissociation Constants | 1.76pKa = 2.27 (1,2,4-triazole) |
| Collision Cross Section | 167.5 Ų [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID3020627]156.2 Ų [M+H-H2O]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]163.9 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]163.4 Ų [M+H]+ [CCS Type: TW |
| 沸点 | 579.8±60.0 °C(Predicted) |
| 密度 | 1.05 |
| 引火点 | 9℃ |
| 貯蔵条件 | 2-8°C |
| 外観・状態 | 個体 |
| pKa（酸解離定数） | pKa 1.76±0.1(H2O t=24 I=0.1(NaCl)) (Uncertain) |
| 色 | ホワイトからオフホワイト |
| Merck | 14,4122 |
| ヘンリー定数 | 9.9×107 mol/(m3Pa) at 25℃, HSDB (2015) |
| BCS Class | 1,3 |
| InChI | InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2 |
| InChIKey | RFHAOTPXVQNOHP-UHFFFAOYSA-N |
| SMILES | C1(C=CC(F)=CC=1F)C(O)(CN1N=CN=C1)CN1N=CN=C1 |
| CAS データベース | 86386-73-4(CAS DataBase Reference) |
化学的特性
Fluconazole-D4 is White to Off-White Solid
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 0.5% (1 of 197) of reports.DangerH302 (99.5%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P263, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P308+P316, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 197 reports by companies from 33 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| FDA 要件 | The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl fluconazole, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. |
| Hazard Classes and Categories | Acute Tox. 4 (99.5%) |
| 保管条件 | Fluconazole tablets should be stored in tight containers at a temperature less than 30 °Cfluconazole powder for oral suspension should be stored at a temperature less than 30 °C. |
| 処分方法 | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
| Treatment | In the event of overdose, symptomatic treatment (with supportive measures and gastric lavage if clinically indicated) should be instituted. (L1712) |
| 相互作用 | Concurrent use of fluconazole and short-acting benzodiazepines, such as midazolam, may increase the concentration of the benzodiazepine and increase the psychomotor effectsconsider decreasing the benzodiazepine dose and monitor the patient carefully for signs of increased benzodiazepine exposure.Concurrent use of fluconazole and/or itraconazole with tolbutamide, chlorpropamide, glyburide, or glipizide has increased the plasma concentrations of these sulfonylurea agentshypoglycemia has been notedblood glucose concentrations should be monitored, and the dose of the oral hypoglycemic agent may need to be reduced. |
用途
用途
トリアゾール系抗真菌剤です。 真菌細胞において、膜成分のエルゴステロー ル生合成の抑制作用を示します。
用途
in vitro 及びin vivo においてカンジダ菌に対し強力な作用を示します。トリアゾール系抗真菌 薬作用を示します。
用途
in vitro 及びin vivo においてカンジダ属に対し強力な作用を示します。トリアゾール系抗真菌 薬作用を示します。
用途
フルコナゾールは、深在性真菌症に用いられるアゾール系の抗真菌薬。日本では、ファイザーがジフルカンとして販売しているほか、いくつかの後発医薬品が販売されている。剤形には、カプセル剤、ドライシロップ、注射液がある。 カンジダ属およびクリプトコッカス属による 真菌血症、呼吸器真菌症、消化管真菌症、尿路真菌症、真菌髄膜炎。造血幹細胞移植患者における深在性真菌症の予防。カンジダ属に起因する腟炎および外陰腟炎（カプセル剤のみ）。
用途
トリアゾール系抗真菌剤です。 真菌細胞において、膜成分のエルゴステロー ル生合成抑制作用を示します。
用途
薬理・生理作用研究用。
説明
Fluconazole-D4 is the f i t member of a new generation of stable and orally active antifungals, the triazoles. It is highly effective in the treatment of dermal and vaginal fungal infections; new indications currently under investigation include severe systemic mycoses such as disseminated candidiasis and cryptococcal meningitis in immunocompromised patients.
使用
Labelled Fluconazole (F421000). Used as an antifungal.
一般的な説明
Fluconazole is used to treat adult neutropenic patients with invasive candidiasis (IC).